Obesity – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034
Obesity Emerging Therapy
Thelansis’s “Obesity
Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To
2034″ provides a comprehensive analysis of the emerging competitive
landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL
insights on key emerging therapies and key drug development opportunities in
the indication.
Obesity
Overview
Obesity is a complex, chronic disease
characterized by an excessive accumulation of body fat that can impair health.
It is a major global health concern with an increasing prevalence driven by a
combination of genetic, environmental, social, and psychological factors. From
a life science perspective, obesity is not simply a matter of caloric
imbalance, but involves intricate hormonal and metabolic dysregulation. Adipose
tissue, once considered a passive energy store, is now recognized as a highly
active endocrine organ that secretes adipokines, which influence insulin
sensitivity, inflammation, and appetite regulation. The disease is a
significant risk factor for a wide range of comorbidities, including type 2
diabetes, cardiovascular diseases (hypertension, coronary artery disease,
stroke), certain cancers, non-alcoholic fatty liver disease (NAFLD), and
musculoskeletal disorders.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by surveys* with physician / key opinion leaders:
- Survey findings are corroborated and
enriched by insights from interviews with leading KOLs
*Survey is
customized based on client requirements
Deliverables
format:
- PowerPoint presentation
- MS Excel
Key business
questions answered:
- Detailed emerging competitive
landscape
- Pipeline
analysis
- Target patients
for emerging therapies
- Key companies
- Key mechanism of
actions
- Launch date
estimates, etc.
- Clinical trial landscape analysis
- Target patient
segments
- Trial endpoints
- Trial design
- Recruitment
criteria, etc.
- Unmet Needs and Opportunities
- Performance of
key current therapies
- Top areas of
unmet needs
- Opportunity
sizing for key unmet needs
- Target Product Profiles
- Attributes and
levels
- Physician
likelihood of prescribing
- Expected patient
shares
- KOL insights on key emerging
therapies
- Level of
awareness
- Expected use /
line of therapy
- Extent to fulfil
key unmet needs
- KOL quotes
Read more: Obesity – Emerging Therapy, with Unmet Needs and TPP
Insights Report – 2024 To 2034
Comments
Post a Comment